# US 2008/0076730 A1 · Extended antegrade epicardial coronary infusion of adeno-associated viral vectors for gene therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0076730 A1
- Document ID: US20080076730A1
- Status: Published application
- Kind: A1
- Application number: 11/778,900
- Filed: 2007-07-17
- Published: 2008-03-27
- Earliest claimed: 2006-07-25
- Assignees: Celladon Corporation
- Inventors: Krisztina Zsebo
- Web page: https://patentgrep.com/patent/US20080076730A1

## CPC

- A61K 48/0075: {characterised by an aspect of the delivery route, e.g. oral, subcutaneous}
- A61K 31/7052: having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/06: Antiarrhythmics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to therapies for the treatment of cardiovascular diseases, particularly the delivery of therapeutic agents to heart tissue by direct infusion into the coronary circulation. A preferred embodiment of the invention is a method of treating or preventing a cardiovascular disease by transfecting cardiac cells of a large mammal, the method comprising, identifying an mammal in need of treatment or prevention of a cardiovascular disease, infusing a therapeutic polynucleotide into a blood vessel of the coronary circulation in vivo, where the therapeutic polynucleotide is infused into the blood vessel over a period of at least about three minutes, where the coronary circulation is not isolated or substantially isolated from the systemic circulation of the mammal; and where the therapeutic polynucleotide transfects cardiac cells of the animal resulting in the treatment or prevention of the cardiovascular disease.

## Claims

### Claim 1

A method of treating or preventing a cardiovascular disease by transfecting cardiac cells of a large mammal, the method comprising:
identifying an mammal in need of treatment or prevention of a cardiovascular disease;
infusing a therapeutic polynucleotide into a blood vessel of the coronary circulation in vivo;
wherein said therapeutic polynucleotide is infused into said blood vessel over a period of at least about three minutes;
wherein the coronary circulation is not isolated or substantially isolated from the systemic circulation of the mammal; and
wherein said therapeutic polynucleotide transfects cardiac cells of said mammal resulting in the treatment or prevention of said cardiovascular disease.

### Claim 2 (depends on 1)

The method of claim 1, wherein said polynucleotide is infused into said blood vessel over a period of at least about five minutes.

### Claim 3 (depends on 1)

The method of claim 1, wherein said polynucleotide is infused into said blood vessel over a period of at least about ten minutes.

### Claim 4 (depends on 1)

The method of claim 1, wherein said polynucleotide is infused into said blood vessel over a period of at least about fifteen minutes.

### Claim 5 (depends on 1)

The method of claim 1, wherein said infusion into said blood vessel is at a rate of less than or equal to about 6.0 mL/min.

### Claim 6 (depends on 1)

The method of claim 1, wherein said infusion into said blood vessel is at a rate of less than or equal to about 2.5 mL/min.

### Claim 7 (depends on 6)

The method of claim 6, wherein said infusion into said blood vessel is at a rate of less than or equal to about 2.0 mL/min.

### Claim 8 (depends on 6)

The method of claim 6, wherein said infusion into said blood vessel is at a rate of less than or equal to about 1.2 mL/min.

### Claim 9 (depends on 6)

The method of claim 6, wherein said infusion into said blood vessel is at a rate of less than or equal to about 1.0 mL/min.

### Claim 10 (depends on 6)

The method of claim 6, wherein said infusion into said blood vessel is at a rate of less than or equal to about 0.6 mL/min.

### Claim 11 (depends on 1)

The method of claim 1, wherein said blood vessel is the left coronary artery.

### Claim 12 (depends on 1)

The method of claim 1, wherein the outflow of the coronary circulation is not nonnaturally restricted.

### Claim 13 (depends on 11)

The method of claim 11, wherein transfection of cardiac cells of the anterior lateral ventricle, inferior lateral ventricle, septum and right ventricle is detectable using PCR.

### Claim 14 (depends on 1)

The method of claim 1, wherein the polynucleotide is capable of expressing a protein capable of modulating a cellular activity of the cardiac cells.

### Claim 15 (depends on 14)

The method of claim 14, wherein said cellular activity is a calcium cycling pathway of a cardiomyocyte.

### Claim 16 (depends on 15)

The method of claim 15, wherein said protein is a sarcoplasmic/endoplasmic reticulum ATPase (SERCA).

### Claim 17 (depends on 16)

The method of claim 16, wherein the SERCA is SERCA2a.

### Claim 18 (depends on 1)

The method of claim 1, wherein said polynucleotide is present in a viral vector selected from the group consisting of an adeno-associated virus, an adenovirus, a retrovirus, a herpes simplex virus, a bovine papilloma virus, a lentiviral vector, a vaccinia virus, and a polyoma virus.

### Claim 19 (depends on 18)

The method of claim 18, wherein said viral vector is AAV virus.

### Claim 20 (depends on 18)

The method of claim 18, wherein said viral vector is an AAV2/1 vector.

### Claim 21 (depends on 20)

The method of claim 20, wherein said polynucleotide is operably linked to a CMV-based promoter and packaged in said viral vector.

### Claim 22 (depends on 21)

The method of claim 21, wherein said polynucleotide comprises a SERCA2a coding sequence.

### Claim 23 (depends on 22)

The method of claim 22, wherein said transfection of said cardiac cells increases lateral ventricle fractional shortening.

### Claim 24 (depends on 22)

The method of claim 22, wherein said mammal is human and said disease is congestive heart failure.

### Claim 25 (depends on 1)

The method of claim 1, wherein said polynucleotide is packaged in a DNase resistant particle (DRP) of a viral vector.

### Claim 26 (depends on 25)

The method of claim 25, wherein the total number of DRP infused is less than or equal to an amount selected from the group consisting of 1×1014, 1×1013, 3×1012, 1×1012, 1×1011, 1×1010, 1×109, and 1×108.

### Claim 27 (depends on 26)

The method of claim 26, wherein the total number of DRP infused is less than or equal to 1×1013.

### Claim 28 (depends on 27)

The method of claim 27, wherein the total number of DRP infused is less than or equal to 1×1012, the viral vector is AAV2/1, the polynucleotide comprises a SERCA2a coding sequence, said blood vessel is the left or right coronary artery, and said infusion of said polynucleotide lasts at least about 10 minutes at a flow rate of less than or equal to about 2 mL/min; and
wherein transfection of cardiac cells of the anterior lateral ventricle, inferior lateral ventricle, septum and right ventricle is detectable using PCR.

### Claim 29 (depends on 1)

The method of claim 1, wherein said disease is selected from the group consisting of heart failure, ischemia, arrhythmia, myocardial infarction, congestive heart failure, transplant rejection, abnormal heart contractility, non-ischemic cardiomyopathy, mitral valve regurgitation, aortic stenosis or regurgitation, abnormal Ca2+ metabolism and congenital heart disease.

### Claim 30 (depends on 27)

The method of claim 27, wherein the viral vector is AAV2/1, the polynucleotide comprises a SERCA2a coding sequence, said blood vessel is the left or right coronary artery, and said infusion of said polynucleotide lasts at least about 8 minutes at a flow rate of less than or equal to about 2.5 mL/min; and
wherein transfection of cardiac cells of the anterior lateral ventricle, inferior lateral ventricle, septum and right ventricle is detectable using PCR; and
wherein said transfection of said cardiac cells increases lateral ventricle fractional shortening when measured about 4 months after said infusion by at least 25% as compared to lateral ventricle fractional shortening before infusion of the polynucleotide.

### Claim 31 (depends on 27)

The method of claim 27, wherein the mammal is a human, the viral vector is AAV2/1, the polynucleotide comprises a SERCA2a coding sequence, said blood vessel is the left or right coronary artery, and said infusion of said polynucleotide lasts at least about 10 minutes.

### Claim 32 (depends on 31)

The method of claim 31, wherein the disease of the cardiovascular system is congestive heart failure.

### Claim 33 (depends on 31)

The method of claim 31, wherein said infusion of said polynucleotide is at a flow rate of about 6 mL/min.

### Claim 34 (depends on 31)

The method of claim 31, wherein said transfection of said cardiac cells results in an improvement in a measure of cardiac function selected from the group consisting of expression of SERCA2a protein, fractional shortening, ejection fraction, cardiac output, time constant of ventricular relaxation, and regurgitant volume.

### Claim 35 (depends on 27)

The method of claim 27, further comprising infusing a polynucleotide into an additional blood vessel of the coronary circulation over a period of at least about three minutes.

### Claim 36 (depends on 35)

The method of claim 35, wherein the mammal is a human, the viral vector is AAV2/1, the polynucleotide comprises a SERCA2a coding sequence;
wherein said blood vessel is the left coronary artery, and said infusion of said polynucleotide into the left coronary artery lasts at least about 6 minutes; and
wherein said additional blood vessel is the right coronary artery, and said infusion of said polynucleotide into said right coronary artery lasts at least about 3 minutes.

### Claim 37 (depends on 36)

The method of claim 36, wherein the disease of the cardiovascular system is congestive heart failure.

### Claim 38 (depends on 36)

The method of claim 36, wherein said infusion of said polynucleotide into said left coronary artery and said right coronary artery is at a flow rate of about 6 mL/min.

### Claim 39 (depends on 36)

The method of claim 36, wherein said transfection of said cardiac cells results in an improvement in a measure of cardiac function selected from the group consisting of expression of SERCA2a protein, fractional shortening, ejection fraction, cardiac output, time constant of ventricular relaxation, and regurgitant volume.

### Claim 40

A kit comprising:
a pharmaceutical composition comprising at least 1×1011 DRP of AAV2/1 vector containing a polynucleotide encoding for SERCA2a; and
instructions instructing that a solution comprising at least 0.5×1011 DRP of AAV2/1 vector containing a polynucleotide encoding for SERCA2a should be administered to a patient in need of prevention or treatment of a cardiovascular disease by in vivo infusion into a blood vessel of the coronary circulation wherein said coronary circulation is not isolated or substantially isolated from the systemic circulation of the patient, and wherein said polynucleotide is infused into said blood vessel over a period of at least about three minutes.

### Claim 41 (depends on 40)

The kit of claim 40, wherein said blood vessel is the left or right coronary artery, and said infusion of said polynucleotide is for a period of at least about eight minutes.

### Claim 42 (depends on 19)

The method of claim 19, wherein said viral vector is AAV virus comprising heterologous capsid proteins such that capsid proteins VP1, VP2 and VP3 are not all of the same serotype AAV.

### Claim 43 (depends on 42)

The method of claim 42, wherein said heterologous capsid proteins comprise capsid proteins from AAV1 and AAV2.
